Search Results
Your search for ,UsE matches 11242 pages
Showing 6651 - 6700Image-Guided Biopsies Accurately Identify Patients With Breast Cancer Who Achieve Pathologic Complete Response Following Neoadjuvant Therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response after neoadjuvant systemic therapy consisting of chemotherapy and/or targeted therapy. Should the...
Study Finds Hypofractionated Whole-Breast Irradiation Leads Breast Cancer Radiation Therapies in Cost-Effectiveness, Quality of Life
In a study of three radiation therapies for early-stage breast cancer, one treatment option stands out as offering the most value based on factors including health outcomes, cost-effectiveness, and quality of life. The treatment—hypofractionated whole-breast irradiation—also requires...
Scott Gottlieb, MD, Receives Confirmation as FDA Commissioner
Statement by 2016–2017 ASCO President Daniel F. Hayes, MD, FACP, FASCO: “The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the U.S. Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in...
Pioneer in Geriatric Oncology, Hyman Muss, MD, Continues to Improve Care for Older Patients
Hyman Muss, MD, a pioneer in geriatric oncology, considers himself “a real Brooklyn boy.” His father was a dentist, and his uncle was a general practitioner. “They both practiced out of a small brownstone house in Brownsville-Crown Heights. It was sort of reminiscent of the famous movie The Last...
FDA Oncology Drug Approvals Granted Between August 2016 and May 18, 2017
Pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, received regular approval from the U.S. Food and Drug Administration (FDA) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing...
Clinical Researcher George P. Canellos, MD, Closely Involved With Two of the Most Influential Treatments in Cancer Care
George P. Canellos, MD, President of ASCO from 1993 to 1994, was born in Boston on November 1, 1934. “I came from a business family and never wanted to do business at all. As long back as I can remember, I always found medicine attractive—not only because you could help people, but you could also...
Lack of Access to Transfusions Limits Hospice Use by Patients With Blood Cancer
A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies. The findings, published by Odejide et al in Cancer, help explain...
ASCO and CAP Invite Comment on Focused Update to HER2 Testing Guideline in Breast Cancer
Draft recommendations as part of a focused update to the ASCO/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017. For patients with invasive breast...
Former Vice President Joe Biden and Congressman Kevin Yoder Pledge Continued Support to Conquer Cancer
In a nearly hour-long address to more than 4,500 attendees at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) on April 3, former Vice President Joe Biden lambasted President Trump’s proposed $5.8 billion budget cut to the National Institutes of Health (NIH) and...
OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases
Bisphosphonates were first synthesized more than a century ago, with their initial usage restricted to a range of industrial processes until their potential clinical relevance was appreciated in the late 1960s.1 Then, following development for the treatment of osteoporosis and Paget’s disease of...
Tackling the Obesity and Cancer Epidemic
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining...
Osimertinib in Metastatic EGFR T790M–Mutant NSCLC After EGFR Inhibitor Therapy
On March 30, 2017, osimertinib (Tagrisso) was granted regular approval for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M–mutant non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test, who have progressed...
Palbociclib Combined With Aromatase Inhibitor in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
On March 31, 2017, palbociclib (Ibrance) was granted regular approval for treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.1,2 Palbociclib received...
Six NY Scientists Win Pershing Square Sohn Prize for Young Investigators in Cancer Research
The Pershing Square Sohn Cancer Research Alliance announced the six winners of the 4th annual Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early-career, New York City–area scientists. Recipients receive $200,000 in funding per year for up...
Clark Chen, MD, PhD, to Join University of Minnesota
The University of Minnesota Medical School has announced the addition of Clark Chen, MD, PhD, as the Lyle French Chair in Neurosurgery and the Head of the University of Minnesota Medical School Department of Neurosurgery. He will assume his new position in August 2017. Dr. Chen is a nationally...
Niraparib in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
On March 27, 2017, the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula) was approved for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.1,2...
What Is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer?
As the subtleties of metastatic prostate cancer become increasingly recognized, treatment should evolve accordingly, said Jessica M. Clement, MD, Assistant Professor of Medicine at the University of Connecticut Health System and Neag Cancer Center, Farmington. Of particular interest to Dr. Clement ...
Setting His Presidential Course on Making Precision Medicine a Reality for More Patients
Ensuring that all patients with cancer have access to the potential benefits of precision medicine regardless of where they are treated has been a primary goal of Bruce E. Johnson, MD, FASCO, since the concept was first introduced following completion of the Human Genome Project in 2003. Dr....
Hydroxychloroquine Boosts Antitumor Activity of Neoadjuvant Chemotherapy for Pancreatic Cancer
Adding hydroxychloroquine, an inhibitor of autophagy, to neoadjuvant chemotherapy for pancreatic cancer increases its efficacy and alters the tumor’s molecular profile in a way that may render the tumor more susceptible to immune checkpoint inhibitors, according to interim data from a phase II...
JNCCN 360, the Source for Tumor-Specific News and Treatment Updates, Available Now
Launched during the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™, JNCCN360.org is the latest resource from the Journal of the National Comprehensive Cancer Network (JNCCN). Currently available for breast...
4 Reasons to Use Social Media at the ASCO Annual Meeting
Join the discussion: Use #ASCO17 on Twitter to follow and participate in the Annual Meeting conversation in real time. During this past year’s Annual Meeting, more than 16,000 health-care professionals, researchers, news outlets, patients, advocates, and other participants sent nearly 70,000...
CAR T Cells in Relapsed B-Cell Acute Lymphoblastic Leukemia
Updated results in 51 adults with relapsed B-cell acute lymphoblastic leukemia (ALL) treated with chimeric antigen receptor (CAR) T cells at Memorial Sloan Kettering Cancer Center in New York showed high complete response rates regardless of pre–CAR T disease burden.1 That said, pretreatment...
Marie Bleakley, MD, PhD, Receives Research Grant in Immuno-oncology From Stand Up To Cancer
Marie Bleakley, MD, PhD, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center (Fred Hutch), has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer (SU2C). Dr. Bleakley will use the 3-year, $750,000 award to develop T-cell therapies...
Atezolizumab Improves Overall Survival in Small Subset of Patients With Triple‑Negative Breast Cancer
Triple-negative breast cancer is an aggressive disease with no approved targeted therapy, and it remains challenging to treat. Early data from a phase I study suggest that the PD-L1 inhibitor atezolizumab (Tecentriq) can extend the lives of a subset of women who respond to this checkpoint...
FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site-Agnostic Indication
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...
Anticipate Sexual Dysfunction in Patients on Aromatase Inhibitors
For patients with breast cancer starting on aromatase inhibitors, sexual dysfunction is commonly reported. Early intervention may lessen its impact—but it’s not an easy fix, says a specialist in this area, Leslie R. Schover, PhD. Dr. Schover is Founder of Will2Love, an online sexual health program ...
Expert Point of View: Julie Margenthaler, MD
“This study of 2,759 patients with ductal carcinoma in situ provides data for women who are considering their surgical options,” said Julie Margenthaler, MD, a breast surgeon at Washington University of Medicine, St. Louis, and Communications Chair of the American Society of Breast Surgeons...
Expert Point of View: Judy C. Boughey, MD
“Inflammatory breast cancer represents the aggressive end of the spectrum of breast cancer at presentation. It is encouraging It to see the high 5-year breast cancer–specific survival rates reported in this cohort of 114 women,” said Judy C. Boughey, MD, a breast surgeon at the Mayo Clinic,...
Optimizing Treatment for Elderly Patients With Glioblastoma
In 2005, Stupp and colleagues published their landmark paper demonstrating in a randomized phase III trial that the addition of temozolomide to radiation increased overall survival in patients with newly diagnosed glioblastoma. Notably, patients over age 70 years were excluded from this study.1...
Managing Small Renal Masses: A Point-by-Point Consideration of ASCO’s Clinical Practice Guideline
As reviewed in this issue of The ASCO Post, a recent issue of the Journal of Clinical Oncology featured an ASCO Clinical Practice Guideline on the management of small renal masses reported by Finelli and colleagues.1 This comprehensive guideline is written by a group of well-regarded and...
Outcomes in Patients With Double-Hit Lymphoma After First Complete Remission
In an analysis reported in the Journal of Clinical Oncology, Landsburg et al found no significant benefit of consolidative autologous stem cell transplantation in patients with double-hit lymphoma after first complete remission. They also found evidence of poorer outcome with front-line R-CHOP...
Intratumoral Plasmid Interleukin-12 Boosts Response to Pembrolizumab
In patients with stage III/IV melanoma, immunologically “cold” tumors were rendered immunologically active through intratumoral injections of plasmid interleukin-12 (IL-12) combined with pembrolizumab (Keytruda).1 Describing the approach at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium,...
ASCO Provisional Clinical Opinion on Hormonal Therapy for Castration-Resistant Prostate Cancer
On April 25, ASCO issued a provisional clinical opinion on the use of second-line hormonal therapy for men with castration-resistant prostate cancer who have not yet received chemotherapy. The recommendations of this provisional clinical opinion were informed by evidence from a systematic review of ...
ASPO Honors Kurt Ribisl, PhD, With Joseph W. Cullen Memorial Award
The American Society of Preventive Oncology (ASPO) has named Kurt Ribisl, PhD, the recipient of the 2017 Joseph W. Cullen Memorial Award. ASPO presented the honor at its Annual Meeting in Seattle. In addition to receiving the award, Dr. Ribisl presented a talk on finding a solution for...
Accrual of Older Patients to Breast Cancer Trials: A Critical Need
As the U.S. population ages,1 the number of older women with breast cancer will increase,2 as well as the number of patients with frailty and other comorbid medical conditions. These patients are at increased risk for toxicity and functional decline during their breast cancer treatment course....
Rates of Oral HPV Infection Plummet After Vaccination
Vaccination against the human papillomavirus (HPV) reduced the risk of acquiring oral HPV infections by 88%, in one of the first large studies to explore vaccination’s impact in the oropharynx. The study will be presented at the 2017 ASCO Annual Meeting, and the findings were released in advance of ...
Prognostic Model May Prove Useful After Nephrectomy
A prognostic model proved able to accurately predict long-term outcomes for patients with stage I to III renal cell carcinoma, the developers of the instrument reported at the 2017 National Comprehensive Cancer Network Annual Conference.1 The model was derived from molecular tissue analysis and...
Provision of Genetic Services to Women With Breast Cancer: We Must Do Much Better
Genetic testing for inherited cancer susceptibility is increasingly part of the care of cancer patients and their relatives. Early clinical guidelines recommended BRCA1/2 testing for women diagnosed with breast or ovarian cancer if they also have a significant family cancer history or Ashkenazi...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...
One in Five Cancers Diagnosed in the United States Is a Rare Cancer
About one in five cancer diagnoses in the United States is a rare cancer, according to new research from the American Cancer Society. The report, published by DeSantis et al in CA: A Cancer Journal for Clinicians, found rare cancers account for more than two in three cancers occurring in children...
Cholesterol-Lowering Medication Use and Breast Cancer Outcome
In a study reported in the Journal of Clinical Oncology, Signe Borgquist, MD, PhD, of Lund University, Sweden, and colleagues found that use of cholesterol-lowering medication during adjuvant endocrine therapy was associated with a reduced risk of breast cancer recurrence in hormone...
ASCO CEO Reflects on His First Year in Office and What Is Ahead
June 27, 2017, marks the 1-year anniversary since Clifford A. Hudis, MD, FACP, FASCO, began his tenure as Chief Executive Officer of ASCO. With the launch of the national Cancer Moonshot and the changes in the White House and Congress, it has been a year of tremendous activity drawing on all of...
The Role of Meditation in Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, present the case...
Recognizing Major Role of Random Mutations in Causing Cancer Does Not Diminish Importance of Primary Prevention
Random mistakes made during DNA replication are responsible for about two-thirds of the mutations that cause human cancers, according to a study reported in Science.1 Recognizing the role of these replication errors “does not diminish the importance of primary prevention but emphasizes that not all ...
First Extensive Immune Profiling of Sarcomas Shows Possible Susceptibility to Immunotherapy
Sarcomas come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers. However, a study published by Pollack et al in the journal Cancer suggests how both existing and ...
Economic Impact of Chronic Conditions on Cancer Survivors
There is a higher prevalence of chronic health conditions among cancer survivors vs people without a history of cancer, and the presence of chronic conditions is associated with greater annual medical expenditures compared with the absence of such conditions in cancer survivors. These findings were ...
RECIL 2017: New Response Evaluation Criteria in Lymphoma Clinical Trials
New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the Response Evaluation Criteria in Solid Tumors (RECIST). The new criteria were reported by Younes et al in Annals ...
AUA 2017: Studies Highlight Shifts in Prostate Cancer Screening and Management
Active surveillance in men under 60, use of telemedicine in the management of prostate cancer, and physicians' personal prostate cancer screening preferences were all highlighted at the 2017 Annual Scientific Meeting of the American Urological Association (AUA). Active Surveillance for Low-Risk...
Alcohol Consumption May Be Associated With Higher Risk of Breast Cancer in African American Women
Alcohol intake was associated with an increased risk of breast cancer in a large study of African American women, indicating that they, like white women, may benefit from limiting their alcohol consumption, according to results of a study published by Williams et al in Cancer Epidemiology,...
Blended Cognitive Behavior Therapy and Fear of Recurrence in Cancer Survivors
A Dutch study (SWORD) has shown that blended cognitive behavioral therapy (CBT)—mixing face-to-face and online sessions—reduced the fear of recurrence among survivors of breast, prostate, and colorectal cancers. These results were reported by van de Wal et al in the Journal of Clinical...
